MPS Connect
MPS Connect is a new innovation that promotes good mental health and enables early intervention for those in need of greater support with their mental health.
It combines the clinically proven self-help content of My Possible Self, the mental health app listed at the NHS Apps Library, with remote patient monitoring and data analytics and insights. This enables clinicians to monitor and manage mental health needs among a population area.
About
MPS Connect is a new innovation that promotes good mental health and enables early intervention for those in need of greater support with their mental health.
It combines the clinically proven self-help content of My Possible Self, the mental health app listed at the NHS Apps Library, with remote patient monitoring and data insights provided by sister company Inhealthcare.
This enables clinicians to monitor and manage mental health needs among a population area. MPS Connect offers full interoperability with all major NHS systems via Inhealthcare, a UK market leader in remote patient monitoring.
- MPS Connect monitors the patient journey through various NHS systems from the first presentation onwards, joining the dots in a fragmented system
- MPS Connect provides individuals with clinically proven resilience-building tools along the way
- MPS Connect delivers data and insights to help you make decisions and allocate resources as efficiently as possible
My Possible Self launched as an app in late 2017 and was listed at the NHS Apps Library in summer 2018. The company developed MPS Connect during the NHS-backed DigitalHealth.London Accelerator programme 2018-19 with input from clinicians and commissioners.
MPS Connect enables clinician to triage people presenting with mental health concerns at a single point of access and signpost them to the appropriate NHS services, while monitoring their progress through the various pathways via self-report questionnaires.
People who follow the learning modules in MPS experienced an improvement in symptoms of stress, anxiety and mild-to-moderate depression within seven weeks in a randomised control trial: https://bmcpsychiatry.biomedcentral.com/articles/10.1186/1471-244X-13-312
